Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4217-4221

  Maruyama, Riichiroh ^a   Wataya, Hiroshi ^a   Seto, Takashi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Gefitinib; Non small cell lung cancer; Post initial gefitinib therapy; Treatment failure

Indexed keywords

DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 71949115227     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Taketa I, Smit EK, Averbush SD, Macleod A, Feyereislova A, Dong RP and Baselga J: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
2. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbush SD, Ochs JS and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003. (Pubitemid 37432975)
3. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa™ Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
4. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N and Fukuoka M: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small cell lung cancer. J Clin Oncol 26: 4244-4252, 2008.
5. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM and Douillard JY: Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
6. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
7. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
8. Sobin LH and Wittenkind C: TNM Classification of Malignant Tumors. New York: Wiley-Liss, 1997.
9. Travis WD CT, Corrin B, Shimosato Y, Brambilla E and Collaborators from 14 Countries: World Health Organization. International Histological Classification of Tumors. Histological Typing of Lung and Pleural Tumors. Third Edition. Berlin: Springer Verlag, 1999.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
11. Kaplan E and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
13. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
14. Rosenbaum PR and Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41-55, 1983.
15. Giaccone G, Herbst RS, Manegold C, Scagliotti GV, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbush SD, Wolf MK, Rennie P and Fandi A: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
16. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti GV, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbush SD, Ochs JS, Grous J and Fandi A: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004. (Pubitemid 41103589)
17. Shoji F, Yano T, Yoshino I, Mori D, Yamasaki F, Kohno H and Maehara Y: The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. Euro J Surg Oncol 34: 89-93, 2008. (Pubitemid 350296761)
18. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH and Miller VA: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13: 5150-5155, 2007. (Pubitemid 47502083)
19. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E and Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational study (BRiTE). J Clin Oncol 26: 5326-5334, 2008.
20. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H and Kim JH: Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol 25: 2528-2533, 2007. (Pubitemid 47041225)
21. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH and Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Janne PA: MET amplification leads to gefitinib resistance in lung cancers by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
23. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski, MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA and Pao W: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501, 2006. (Pubitemid 44799723)